Palisade Bio (NASDAQ:PALI – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($2.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.35) by $1.03, Zacks reports.
Palisade Bio Price Performance
Shares of NASDAQ:PALI traded down $0.09 on Wednesday, hitting $2.29. The company’s stock had a trading volume of 46,666 shares, compared to its average volume of 410,091. Palisade Bio has a 1 year low of $2.18 and a 1 year high of $22.35. The company has a market capitalization of $3.05 million, a PE ratio of -0.17 and a beta of 1.36. The company has a 50-day simple moving average of $3.40 and a 200 day simple moving average of $4.23.
Wall Street Analyst Weigh In
Separately, Maxim Group cut their price objective on Palisade Bio from $22.50 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday.
Palisade Bio Company Profile
Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.
Further Reading
- Five stocks we like better than Palisade Bio
- How Can Investors Benefit From After-Hours Trading
- Rocket Lab is the Right Stock for the Right Time
- How to Evaluate a Stock Before Buying
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- How to Plot Fibonacci Price Inflection Levels
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.